Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival

@article{Tefferi2016MomelotinibTI,
  title={Momelotinib Therapy in Myelofibrosis: 6-Years Follow-up Data on Safety, Efficacy and the Impact of Mutations on Overall and Relapse-Free Survival},
  author={A. Tefferi and D. Barraco and T. Lasho and K. Begna and A. Al-Kali and W. Hogan and M. Litzow and C. Hanson and R. Ketterling and N. Gangat and A. Pardanani},
  journal={Blood},
  year={2016},
  volume={128},
  pages={1123-1123}
}
  • A. Tefferi, D. Barraco, +8 authors A. Pardanani
  • Published 2016
  • Medicine
  • Blood
  • Background: Momelotinib is a JAK 1/2 inhibitor that is active in the treatment of myelofibrosis (MF); a previous phase 1/2 study included 100 consecutive patients from the Mayo Clinic (Leukemia. 2015;29:741). In the current long-term study of these 100 patients, we provide a cumulative account of short and long term efficacy and toxicity data, as well as survival analysis. Methods: The current study represents sponsor-independent analysis. The study patients are part of a larger (n=166) phase-1… CONTINUE READING
    8 Citations

    Topics from this paper.

    Investigational Janus kinase inhibitors in development for myelofibrosis
    • 8
    Management of myelofibrosis: JAK inhibition and beyond
    • 10
    Developmental Therapeutics in Myeloproliferative Neoplasms
    • 11
    Pharmacotherapy of Myelofibrosis
    • 4
    • Highly Influenced
    The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    • 16